UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 57,130 Shares of Encompass Health Co. (NYSE:EHC)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Encompass Health Co. (NYSE:EHC - Free Report) by 18.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 367,598 shares of the company's stock after purchasing an additional 57,130 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.36% of Encompass Health worth $33,948,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in EHC. Colonial Trust Co SC bought a new stake in Encompass Health in the fourth quarter worth approximately $29,000. Transce3nd LLC bought a new stake in Encompass Health in the fourth quarter worth approximately $40,000. CBIZ Investment Advisory Services LLC increased its holdings in Encompass Health by 38.7% in the fourth quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company's stock worth $42,000 after purchasing an additional 127 shares in the last quarter. V Square Quantitative Management LLC increased its holdings in Encompass Health by 43.8% in the fourth quarter. V Square Quantitative Management LLC now owns 581 shares of the company's stock worth $54,000 after purchasing an additional 177 shares in the last quarter. Finally, Signaturefd LLC increased its holdings in Encompass Health by 21.6% in the fourth quarter. Signaturefd LLC now owns 704 shares of the company's stock worth $65,000 after purchasing an additional 125 shares in the last quarter. 97.25% of the stock is currently owned by institutional investors.

Encompass Health Stock Up 0.4%

Encompass Health stock traded up $0.47 during trading on Thursday, hitting $119.99. 552,940 shares of the company were exchanged, compared to its average volume of 698,940. The business's 50 day moving average is $109.12 and its 200 day moving average is $101.77. Encompass Health Co. has a 52 week low of $82.74 and a 52 week high of $121.96. The company has a market capitalization of $12.09 billion, a P/E ratio of 26.90, a PEG ratio of 2.31 and a beta of 0.91. The company has a current ratio of 1.05, a quick ratio of 1.04 and a debt-to-equity ratio of 0.84.

Encompass Health (NYSE:EHC - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The company reported $1.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.18. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. The business had revenue of $1.46 billion during the quarter, compared to the consensus estimate of $1.43 billion. During the same quarter in the prior year, the company posted $1.12 earnings per share. Encompass Health's revenue was up 10.6% compared to the same quarter last year. Analysts predict that Encompass Health Co. will post 4.8 earnings per share for the current year.

Encompass Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Tuesday, July 1st will be given a $0.17 dividend. The ex-dividend date of this dividend is Tuesday, July 1st. This represents a $0.68 annualized dividend and a yield of 0.57%. Encompass Health's dividend payout ratio is currently 14.05%.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Barclays lifted their target price on Encompass Health from $118.00 to $129.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Truist Financial restated a "buy" rating and set a $135.00 price objective (up previously from $116.00) on shares of Encompass Health in a report on Monday, April 28th. Royal Bank of Canada boosted their price objective on Encompass Health from $110.00 to $125.00 and gave the company an "outperform" rating in a report on Monday, April 28th. KeyCorp boosted their price objective on Encompass Health from $122.00 to $135.00 and gave the company an "overweight" rating in a report on Tuesday. Finally, William Blair restated an "outperform" rating on shares of Encompass Health in a report on Friday, February 7th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $122.71.

Insiders Place Their Bets

In other news, CEO Mark J. Tarr sold 118,384 shares of the stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $121.53, for a total transaction of $14,387,207.52. Following the completion of the transaction, the chief executive officer now owns 527,070 shares in the company, valued at approximately $64,054,817.10. This represents a 18.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Elissa Joy Charbonneau sold 4,279 shares of the stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $116.61, for a total value of $498,974.19. Following the transaction, the insider now owns 11,958 shares of the company's stock, valued at $1,394,422.38. The trade was a 26.35% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 132,663 shares of company stock valued at $16,034,082. Insiders own 2.00% of the company's stock.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.